CDH17 is an adhesion molecule from the cadherins family and assumes a significant role during embryogenesis and for maintenance of water-tight junctions in gastrointestinal tract.

Our founder/CEO Dr John Luk identified and patented CDH17 as a therapeutic cancer target, where aberrant expressions of CDH17 is closely associated with the development, progression and metastasis of various GI cancers.